Protocol Ledger

NCT05534984 · Phase III · TERMINATED

Study of Tecovirimat for Human Mpox Virus

Interventional Phase III clinical trial protocol NCT05534984 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-08 Enrollment: 719 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05534984
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)719 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05534984
Protocol FieldVerified Registry Value
NCT IdentifierNCT05534984
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment719 participants (ACTUAL)
Registered Start Date2022-09-08
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI